Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation

被引:300
作者
Katz, A
Strom, EA
Buchholz, TA
Thames, HD
Smith, CD
Jhingran, A
Hortobagyi, G
Buzdar, AU
Theriault, R
Singletary, SE
McNeese, MD
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
D O I
10.1200/JCO.2000.18.15.2817
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The objective of this study was to determine locoregional recurrence (LRR) patterns after mastectomy and doxorubicin-based chemotherapy to define subgroups of patients who might benefit from adjuvant irradiation, Patients and Methods: A total of 1,031 patients were treated with mastectomy and doxorubicin-based chemotherapy without irradiation on five prospective trials. Median follow-up time wets 116 months. Rates of isolated and total LRR (+/- distant metastasis) were calculated by Kaplan-Meier analysis. Results: The 10-year actuarial rates of isolated LRR were 4%, 10%, 21%, and 22% for patients with zero, one to three, four to nine, or greater than or equal to 10 involved nodes, respectively (P < .0001), Chest wall (68%) and supraclavicular nodes (41%) were the most common sites of LRR. T stage (P < .001), tumor size (P < .001), and greater than or equal to 2-mm extranodal extension (P < .001) were also predictive of LRR. Separate analysis was performed for patients with T1 or T2 primary disease and one to three involved nodes (n = 404). Those with fewer than 10 nodes examined were at increased risk of LRR compared with those with greater than or equal to 10 nodes examined (24% v 11%; P = .02). Patients with tumor size greater than 4.0 cm or extranodal extension greater than or equal to 2 mm experienced rates of isolated LRR in excess of 20%, Each of these factors continued to significantly predict for LRR in multivariate analysis by Cox logistic regression. Conclusion: Patients with tumors greater than or equal to 4 cm or at least four involved nodes experience LRR rates in excess of 20% and should be offered adjuvant irradiation. Additionally, patients with one to three involved nodes and large tumors, extranodal extension greater than or equal to 2 mm, or inadequate axillary dissections experience high rates of LRR and may benefit from postmastectomy irradiation. J Clin Oncol 18:2817-2827. (C) 2000 by American Society of Clinical Oncology.
引用
收藏
页码:2817 / 2827
页数:11
相关论文
共 60 条
[1]  
ABE O, 1995, NEW ENGL J MED, V333, P1444
[2]   THE COMBINATION OF RADIOTHERAPY, ADJUVANT CHEMOTHERAPY (CYCLOPHOSPHAMIDE-DOXORUBICIN-FTORAFUR) AND TAMOXIFEN IN STAGE-II BREAST-CANCER - LONG-TERM FOLLOW-UP RESULTS OF A RANDOMIZED TRIAL [J].
BLOMQVIST, C ;
TIUSANEN, K ;
ELOMAA, I ;
RISSANEN, P ;
HIETANEN, T ;
HEINONEN, E ;
GROHN, P .
BRITISH JOURNAL OF CANCER, 1992, 66 (06) :1171-1176
[3]  
BLUMENSCHEIN GR, 1984, RECENT RES CANCER, V96, P129
[4]   SHORT-COURSE FAC-M VERSUS 1 YEAR OF CMFVP IN NODE-POSITIVE, HORMONE RECEPTOR-NEGATIVE BREAST-CANCER - AN INTERGROUP STUDY [J].
BUDD, GT ;
GREEN, S ;
OBRYAN, RM ;
MARTINO, S ;
ABELOFF, MD ;
RINEHART, JJ ;
HAHN, R ;
HARRIS, J ;
TORMEY, D ;
OSULLIVAN, J ;
OSBORNE, CK .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) :831-839
[5]   10-YEAR RESULTS OF FAC ADJUVANT CHEMOTHERAPY TRIAL IN BREAST-CANCER [J].
BUZDAR, AU ;
KAU, SW ;
SMITH, TL ;
HORTOBAGYI, GN .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (02) :123-128
[6]  
BUZDAR AU, 1988, CANCER, V62, P2098, DOI 10.1002/1097-0142(19881115)62:10<2098::AID-CNCR2820621005>3.0.CO
[7]  
2-B
[8]  
BUZDAR AU, 1990, CANCER, V65, P394, DOI 10.1002/1097-0142(19900201)65:3<394::AID-CNCR2820650303>3.0.CO
[9]  
2-2
[10]  
BUZDAR AU, 1984, CANCER, V53, P384, DOI 10.1002/1097-0142(19840201)53:3<384::AID-CNCR2820530303>3.0.CO